Kronox Lab Sciences Open Offer at ₹157: What It Means and Why Tendering Makes No Sense at ₹192

An open offer for Kronox shareholders, at a price 18% below what the market pays today.

What happened

On 20 August 2026, Indo Borax & Chemicals, with Zenrock Chemicals, agreed to buy 64.26% of Kronox Lab Sciences from its promoters (the Ramani brothers and Joginder Jaswal).

What is an open offer?

When someone buys control of a listed company, SEBI's takeover rules (the SAST Regulations) force the buyer to also offer to buy shares from the public shareholders. Control is changing hands, so ordinary shareholders get a chance to exit too.

That is all this is. It is not an IPO, and it is not a chance to buy new shares. It is Indo Borax offering to buy existing Kronox shares from people who already hold them.

Why is the public offered more than the promoters got?

The rules set the open offer price at the highest of several benchmarks, including the price paid to the promoters and the recent market price.

A simple example: a builder buys your neighbour's flat for ₹1 crore. Flats in your society have recently sold for ₹1.5 crore. If a rule says the builder must also offer to buy your flat at the higher of the two, he must offer you ₹1.5 crore.

Here, Indo Borax paid the promoters about ₹103. Kronox's market price was much higher, so the market benchmark set the public offer at ₹157.27.

Should shareholders tender?

At today's price, no.

A shareholder can sell on the exchange at about ₹192 any day. Tendering into the offer means accepting ₹157, about 18% less. The offer only makes sense if the share price falls below ₹157 before 20 November.

Should anyone buy now to take part?

No. Anyone who holds shares before the window closes can tender, but buying at ₹192 to sell at ₹157 is a guaranteed loss.

The business

Kronox makes high-purity specialty fine chemicals, about 185 products used in pharmaceuticals, nutraceuticals, food and laboratory reagents, from plants in Gujarat, with exports.

In the September 2026 quarter, revenue was ₹26.8 Cr (up 5% year on year) and profit ₹6.4 Cr (down 3.6%). At about ₹192, the market cap is about ₹714 Cr, roughly 25x earnings, with a return on equity of about 27%.

The business is profitable and efficient, but revenue has been flat for two years.

The risk to watch

Until 20 November, the ₹157 offer gives the stock a partial cushion: if the price fell below it, buyers would step in to tender. The cushion is partial because Indo Borax takes at most 25.79%; if more is tendered, it accepts proportionately.

After the offer closes, that cushion is gone. A thinly traded small cap with flat revenue at about 25x earnings could see higher volatility from late November.

If many shareholders tender and Indo Borax ends up above 75%, it will have to bring its stake down to meet the minimum public shareholding rule.

The question no filing answers

The same promoters sold Kronox shares to the public at ₹136 in June 2024. Two years later, they sold control at about ₹103, below their own IPO price and close to half today's market price. The filings do not say why. Possible reasons include the discount at which control blocks in thinly traded small caps often change hands, the consultancy fees and retained 9.95% stake adding to their take, or a market price running ahead of a business whose revenue has stalled.

Verdict

A steady business, sold cheaply by its promoters. For public shareholders, the open offer is irrelevant at today's price, and the period after 20 November is the one to watch.

Educational purposes only. Not investment advice. DYOR.

Sources: SEBI public announcement (20 Aug 2026); Screener; Univest, Q2 FY27 results; Business Standard, IPO price band.